


Global spotlight 20.2: Key additions for the second half of August 2022



There are two newly added evidence syntheses and one update to a living evidence synthesis already included in the public-health measures part of the COVID-END inventory of ‘best’ evidence syntheses. *

**COVID-END assigns ‘best’ status to evidence syntheses based on an assessment of how up-to-date they are (i.e., the date of the last search, with priority given to living reviews), quality (using the AMSTAR tool), and whether there is an evidence profile available (e.g., GRADE).*

Taxonomy section	Title	Type of synthesis	Criteria for best evidence synthesis		
			Date of last search	Quality (AMSTAR) rating	Evidence profile (e.g., GRADE) available
Public-health measures	Immunocompromised patients may produce lower seroconversion rates and antibody titres after receiving a COVID-19 vaccine when compared with immunocompetent individuals; organ transplant recipients probably have the lowest rates of seroconversion, while people with solid cancers probably have the highest	Newly added full review	2021-11-05	6/11	Yes
Public-health measures	In-vitro and empirical studies suggest that mouthwashes may have an antiviral effect against SARS-CoV-2 [Review of studies of mainly unclear or low quality]	Newly added full review	2021-09-30	7/10	No
Public-health measures	[CoronaVac booster against variants of concern] Three doses of CoronaVac [Sinovac] vaccine may not reach the threshold for protection against symptomatic infection produced by the Omicron variant of concern at 30, and 60 days; it may prevent severe disease from the Omicron variant of concern after 90 days after the last dose	Update to living rapid review	2022-08-17	8/9	Yes